IMMP 株価推移チャート
IMMP 財務
Immutep Limited
$0.43
3.35%
$0.01
終値： Jul 01, 16:00:00 GMT-4
$0.44
2.2%
$0
アフターマーケット：Jul 01, 20:00:00 GMT-4
戻る
Immutep Limited (IMMP) 財務
収入
貸借対照表
現金の流れ
年次
四半期
IMMP 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Immutep Limited'in temel mali tabloları nelerdir?
IMMP'ün temel finansal oranları nelerdir?
Immutep Limited'in geliri segment veya coğrafya bazında nasıl dağılıyor?
Immutep Limited kârlı mı?
Immutep Limited'in herhangi bir yükümlülüğü var mı?
Immutep Limited'in tedavüldeki hisse sayısı kaçtır?
主要データ
前終値
$0.4169
始値
$0.4087
当日レンジ
$0.4087 - $0.443
52週レンジ
$0.29 - $3.53
取引高
822.1K
平均取引高
13.7M
配当利回り
--
1株当たり利益(TTM)
-0.34
時価総額
$64.9M
Immutep Limitedとは何ですか？
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing novel immunotherapies for cancer and autoimmune disease. The company is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
